INTRODUCTION {#S1}
============

T helper 17 (T~H~17) cells are a subset of CD4^+^ T helper cells that preferentially secrete interleukin 17A (IL-17A), IL-17F, IL-21, and IL-22 and are important during tissue inflammation and anti-microbial and anti-fungal immunity ([@R38]). Under homeostatic conditions, T~H~17 cells have essential roles in protective immunity against extracellular pathogens at mucosal barriers ([@R38]). However, T~H~17 cells have also been associated with the pathogenesis of several autoimmune diseases, including multiple sclerosis and psoriasis ([@R6]; [@R33]; [@R41]), suggesting that the failure of T~H~17 cell homeostasis may give rise to disease. A significant amount of work has identified key factors that drive T~H~17 cell development and pathogenicity. However, cell-intrinsic mechanisms that negatively regulate T~H~17 cell development and associated inflammatory responses have received less attention. Therefore, a more comprehensive understanding of the factors that both positively and negatively regulate T~H~17 cell development is necessary to better understand T~H~17-mediated autoimmunity and would aid in the development of novel therapeutics to treat T~H~17-mediated diseases.

A number of studies have identified key factors that drive T~H~17 cell development and pathogenicity, including both the nuclear receptors retinoic-acid-receptor-related orphan receptor α and γt ([@R22]; [@R57]). RORγt is considered the lineage-defining transcription factor regulating T~H~17 cell development, and a considerable amount of research has elucidated genomic functions of RORγt. Two other members of the nuclear receptor superfamily, REV-ERBα (NR1D1) and REV-ERBβ (NR1D2), are often co-expressed in the same tissues as the RORs and bind the same DNA response elements, resulting in mutual cross-talk and co-regulation of their shared target genes ([@R25]). Outside of the immune system, the RORs and the REV-ERBs modulate a number of physiological processes but are best known for their roles in the regulation of the circadian rhythm, lipid, and glucose metabolic processes. The REV-ERBs are unique within the nuclear receptor superfamily in that they lack the carboxy-terminal tail of their ligand-binding domain (LBD) called the activation function 2 region (AF-2, helix 12), which is required for coactivator recognition. Thus, in contrast to the RORs, which are constitutive activators of transcription, the REV-ERBs are transcriptional repressors ([@R25]). Collectively, the balance of expression of the RORs and REV-ERBs is critical for dynamic regulation of their target genes ([@R25]). While much is known about RORγt-mediated regulation of T~H~17 cell development and function, little is known about the role of the REV-ERBs in T cell effector functions, specifically proinflammatory T~H~17 cell effector functions and autoimmunity.

Most members of the nuclear receptor superfamily are ligand-regulated transcription factors and represent attractive therapeutic targets, including RORγt. After the initial identification of several synthetic RORγ modulators, including SR1001 and digoxin ([@R21]; [@R50]), countless other RORγ ligands have been identified, demonstrating the tractability of RORγt-targeted treatment of T~H~17-mediated auto-immunity ([@R3]). The REV-ERBs are also ligand-regulated transcription factors, and the porphyrin heme was identified as the endogenous ligand for both REV-ERBα and REV-ERBβ ([@R47]; [@R59]). We and others have identified and characterized synthetic ligands that modulate the activity of the REV-ERBs both *in vitro* and *in vivo* ([@R2]; [@R26]; [@R51]). We previously synthesized and characterized SR9009 and SR9011 for their activity and specificity to target the REV-ERBs, demonstrating that *in vivo* pharmacological modulation of REV-ERB activity affected REV-ERB-mediated processes, including regulation of the circadian rhythm, glucose, and lipid metabolic processes ([@R51]). Despite the well-documented overlap in genetic programs between the RORs and REV-ERBs in tissues outside of the immune system ([@R25]), the role for the REV-ERBs in T~H~17 cell development is still poorly understood. Furthermore, given the massive pharmaceutical effort focused on developing potent RORγ-modulators, small-molecule modulators of REV-ERB activity could represent a novel therapeutic target for the treatment of T~H~17-mediated autoimmunity.

While REV-ERBα was previously demonstrated to diurnally regulate T~H~17 cell frequencies *in vivo* ([@R62]), its function in the context of proinflammatory settings and autoimmunity remains poorly defined. Here, we show that REV-ERBα is expressed during T~H~17 cell development and its presence is required for dampening T~H~17-mediated proinflammatory cytokine expression. Overexpression of REV-ERBα suppressed T~H~17 cell development, whereas genetic deletion of REV-ERBα resulted in enhanced T~H~17 cell development *in vitro* and exacerbated autoimmune responses *in vivo*. We found that while REV-ERBα directly repressed *Nfil3* ([@R62]), it also competed with RORγt for binding at the *Il17a* promoter and CNS-5 enhancer region. We also discovered that REV-ERBα binds within the *Rorc* promoter region, suggesting potential crosstalk and autoregulation among these receptors for controlling T~H~17 cytokine expression. Finally, the use of REV-ERB-specific small molecules that we developed suppressed T~H~17 cell development *in vitro* and the development of T~H~17-mediated autoimmunity *in vivo* and was effective when used in a "treatment mode" in several models of autoimmunity and chronic inflammation. However, unlike RORγ modulators, REV-ERB modulators did not have effects on the thymus. Collectively, our data suggest that REV-ERBα functions outside of its classical role as a core member of the circadian clock under proinflammatory conditions and importantly, is a key cell-intrinsic negative regulator of T~H~17 cell proinflammatory immune responses.

RESULTS {#S2}
=======

REV-ERBα Is Upregulated in T~H~17 Cells {#S3}
---------------------------------------

To determine whether the REV-ERBs were expressed during CD4^+^ T helper cell development, we differentiated naive CD4^+^ T cells into T~H~1, T~H~2, T~H~17, or inducible T regulatory cells (iTregs). REV-ERBα was upregulated at the mRNA level in T~H~17 cells, whereas REV-ERBβ was not ([Figure 1A](#F1){ref-type="fig"}). We next performed a kinetic analysis and discovered the expression pattern of REV-ERBα was similar to that of the RORs, whereas REV-ERBβ was downregulated during development ([Figures 1B and 1C](#F1){ref-type="fig"}). The similar expression pattern profiles between the RORs and REV-ERBα are consistent with other published data demonstrating that the RORs drive REV-ERBα expression through conserved ROR response elements (ROREs) within its promoter region ([@R48]; [@R54]). Furthermore, the disconnect in expression between REV-ERBα and REV-ERBβ is unique given that the REV-ERBs typically have overlapping tissue expression patterns ([@R25]), suggesting that REV-ERBα may play a role in the regulation of T~H~17 cell development.

The REV-ERBs Repress T~H~17 Cell Development {#S4}
--------------------------------------------

To better assess the function of the REV-ERBs in T~H~17 cells, we retrovirally overexpressed an empty vector (MIGR1), REV-ERBα, or REV-ERBβ in T~H~17 cells. Although the expression of both REV-ERBs inhibited IL-17A and IL-17F expression, REV-ERBα was more potent ([Figure 1D](#F1){ref-type="fig"}). The inhibitory effect of the REV-ERBs appeared to be T~H~17-cell specific because it did not affect the expression of Foxp3 in iTreg cells ([Figure S1A](#SD1){ref-type="supplementary-material"}). Interestingly, overexpression of REV-ERBα but not REV-ERBβ resulted in decreased RORγt expression in transduced T~H~17 cells ([Figure 1E](#F1){ref-type="fig"}). Quantitative real-time PCR analysis on sorted transduced samples demonstrated a significant decrease in expression of T~H~17-cell signature genes and *Nfil3* ([Figure 1F](#F1){ref-type="fig"}). Although the REV-ERBα-mediated repression on *Nfil3* was consistent with previously published work ([@R62]), the reduction in T~H~17-cell signature genes was not. Given the striking effects of REV-ERBα on *Nfil3* and T~H~17-mediated gene expression, we wanted to assess how *Nfil3* fit into this paradigm. We retrovirally overexpressed or knocked down *Nfil3* in T~H~17 cells and found each to have little effect on IL-17A expression ([Figures S1B](#SD1){ref-type="supplementary-material"} and [S1C](#SD1){ref-type="supplementary-material"}). This is consistent with a prior study that demonstrated similar results ([@R9]). Collectively, our data suggest that REV-ERBα may be playing a more direct role in T~H~17 cell development than previously identified.

To better understand the transcriptional programs dictated by the REV-ERBs during T~H~17 cell development, we performed RNA sequencing on T~H~17 cells transduced with an empty vector, REV-ERBα, or REV-ERBβ retrovirus. Consistent with our quantitative real-time PCR data, REV-ERBα transduced cells repressed a number of T~H~17 cell signature genes, including the "core" RORγt target genes *Il17a*, *Il23r*, *TGFβ3*, *Ccl20*, and *Ltb4r1* ([@R9]), relative to MIGR1 controls (adjusted p value \[p. adj.\] \< 0.05) ([Figure 1G](#F1){ref-type="fig"} and [Table S1](#SD1){ref-type="supplementary-material"}). KEGG pathway analysis indicated that REV-ERBα differentially regulated genes associated with inflammatory bowel disease (IBD), which is consistent with the involvement of T~H~17 cells in the pathogenesis of IBD ([@R17]; [@R23]; [@R31]), cytokine-cytokine receptor interactions, Jak-STAT signaling pathways, T cell receptor signaling, and the circadian rhythm ([Figure 1H](#F1){ref-type="fig"}). Overexpression of REV-ERBβ had a modest effect on global T~H~17 cell gene changes relative to REV-ERBα. These data suggest that REV-ERBα is a potent repressor of the T~H~17 cell genetic program.

Cell Intrinsic Role for REV-ERBα in Restraining T~H~17 Cell Development and Inflammatory Responses *In Vivo* {#S5}
------------------------------------------------------------------------------------------------------------

We next used REV-ERBα^−/−^ mice ([@R8]) to explore the endogenous role of REV-ERBα in T~H~17 cell development. Immune phenotyping revealed no overt differences between REV-ERBα^+/+^ (wild-type \[WT\]) and REV-ERBα^−/−^ (KO) mice ([Figures S2A--S2C](#SD1){ref-type="supplementary-material"}). We differentiated WT and KO naive CD4^+^ T cells under T~H~1-, T~H~2-, T~H~17-, or iTreg-polarizing conditions and observed a significant increase in the frequency of IL-17A^+^IL-17F^+^ cells and the expression of RORγt in T~H~17 cells ([Figure 2A](#F2){ref-type="fig"}). Similar results were observed across various T~H~17 cell culture conditions, including pathogenic T~H~17 conditions ([@R32]; [@R45]), with little to no effect on the development of T~H~1 and T~H~2 cells ([Figures S3A--S3C](#SD1){ref-type="supplementary-material"}). Although a prior study found that REV-ERBα deficiency resulted in decreased IL-17A production *in vitro*, differences in the culture conditions, protocols, and mouse strains could account for the different outcomes ([@R62]). However, REV-ERBα deficiency resulted in reduced expression of Foxp3 and increased expression of RORγt in iTreg cultures ([Figure S3D](#SD1){ref-type="supplementary-material"}). Because overexpression of REV-ERBα did not affect iTreg development *in vitro*, these results suggested this was possibly through REV-ERBα-dependent effects on RORγt expression. REV-ERBα deficiency also increased the expression of T~H~17 signature genes as well as *Nfil3* ([Figure 2B](#F2){ref-type="fig"}), consistent with a direct relief of repression expected when a transcriptional repressor is deleted ([@R7]; [@R12]). Finally, we performed RNA sequencing to examine the global transcriptional effects of REV-ERBα deficiency on T~H~17 cell development. Similar to our overexpression studies ([Figure 1](#F1){ref-type="fig"}), REV-ERBα-deficient T~H~17 cells differentially expressed numerous T~H~17 cell signature genes, including *Il17a*, *Il17f, Ccl20*, and *Lta*, relative to WT control cells (p. adj. \< 0.05) and regulated similar pathways identified by KEGG pathway analysis ([Figure 2C](#F2){ref-type="fig"} and [Table S2](#SD1){ref-type="supplementary-material"}). Because REV-ERBα and RORγ bind to the same DNA response elements, we compared our data to previously published data that assessed RORγ knockout T~H~17 cells ([@R9]). Although we observed only a small overlap in genes, most of the overlapping genes were the core RORγt target genes ([@R9]) ([Figure 2C](#F2){ref-type="fig"}). These data indicate that REV-ERBα affects T~H~17 cell development through several mechanisms, including RORγt-dependent T~H~17 cell cytokine expression.

To determine whether REV-ERBα influenced T~H~17-mediated autoimmunity, we immunized WT and KO mice with a myelin oligodendrocyte glycoprotein peptide (MOG35--55) to induce experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Signs of disease were exacerbated, and the onset of disease was slightly earlier in KO mice compared to WT littermate controls ([Figure 2D](#F2){ref-type="fig"}). We observed an increased frequency of CD4^+^ T cells infiltrating the CNS of the KO mice at the peak of disease ([Figure 2E](#F2){ref-type="fig"}). Of the infiltrating CD4^+^ T cells in the CNS, the overall frequency of RORγt^+^ cells was elevated ([Figure 2G](#F2){ref-type="fig"}). This correlated with the increased expression of IL-17A^+^ T cells in the CNS, whereas the percent of anti-inflammatory Foxp3^+^ Tregs was significantly decreased ([Figures 2F and 2G](#F2){ref-type="fig"}). Because T~H~17 cells can give rise to T~H~1-like cells that produce IFNγ, and acquisition of IFNγ has been linked to their pathogenicity in several models of chronic disease ([@R14]; [@R18]; [@R31]), we assessed the frequency of IL-17A^+^, IL-17A^+^IFNγ^+^, and IFNγ^+^ T cells in the CNS ([Figure 2H](#F2){ref-type="fig"}). There was a significant increase in the IL-17A^+^IFNγ^+^ population in KO mice compared to WT controls. These results indicated that the loss of REV-ERBα leads to increased proinflammatory responses *in vivo*.

REV-ERBα Deficiency Exacerbates the Development of Colitis {#S6}
----------------------------------------------------------

To determine the T cell-specific effects of REV-ERBα *in vivo*, we sorted naive CD4^+^ T cells from WT and KO mice and adoptively transferred them into *Rag1*^−*/*−^ recipients to track the development of colitis, which is another T~H~17-driven inflammatory disorder ([@R17]; [@R31]) by using PBS-sham injections as a control. The transfer of KO cells resulted in more severe weight loss and intestinal inflammation than WT cells ([Figure 3A](#F3){ref-type="fig"}). Mice receiving KO T cells had an increased frequency of RORγt^+^ T~H~17 cells and decreased frequency of Foxp3^+^ Tregs relative to WT recipient mice in spleens and mesenteric lymph nodes (mLNs) ([Figures 3B--3D](#F3){ref-type="fig"}). Mice receiving KO T cells also had an increased frequency of IL-17A^+^ and pathogenic IL-17A^+^IFNγ^+^ cells ([Figure 3E](#F3){ref-type="fig"}). The expression of T~H~17-associated cytokines (*Il17a*, *Il17f*, and *Il22*), proinflammatory cytokines (*Il1b*, *Il6*, *Tnfa*, and *IFNγ*), and genes activated downstream of IL-17A and IL-17F and IL-22 signaling (*Cxcl2* and *Cxcl10*) were increased at the mRNA level in whole-tissue homogenates of the proximal colons of mice receiving KO T cells ([Figure 3F](#F3){ref-type="fig"}). Finally, histological analysis of the proximal colons demonstrated increased cellular infiltration, broadening of the crypts, and epithelial hyperplasia in mice receiving KO T cells compared to WT controls ([Figure 3G](#F3){ref-type="fig"}). Similar results were observed in the distal colon of the recipient mice (data not shown). These results indicate that the loss of REV-ERBα promotes T cell-mediated colitis, leading to increased frequencies of proinflammatory T~H~17 and IFNγ-producing T~H~17 cells, reinforcing the role of REV-ERBα as a negative regulator of proinflammatory T~H~17 responses.

REV-ERBα Competes with RORγt To Repress T~H~17 Cell Development {#S7}
---------------------------------------------------------------

We next sought to delineate the molecular mechanisms underlying REV-ERBα-dependent repression of T~H~17 cell development. Because the RORs and REV-ERBs bind to the same genomic DNA response element sequence, an RGGTCA half-site preceded by a 5^′^-AT-rich region (RORE and/or REV-ERB response element \[RevRE\]), we wanted to determine if REV-ERBα could bind and repress within the *Il17a* locus, a known RORγt target gene ([Figure 4A](#F4){ref-type="fig"}). Cotransfection assays in HEK293 cells using an *Il17a+CNS5* luciferase reporter construct ([@R63]) demonstrated that REV-ERBα repressed *Il17a+CNS5-*luciferase driven activity in a concentration-dependent manner ([Figure 4B](#F4){ref-type="fig"}). This effect was dependent on the ability of REV-ERBα to bind DNA because deletion of its DNA-binding domain (DBD) had no effect on luciferase activity, whereas the REV-ERBα DBD alone also dose-dependently inhibited *Il17a+CNS5*-luciferase driven activity. We next performed competition experiments in HEK293 cells to determine if REV-ERBα competes with RORγt at their shared RORE and/or RevRE in the *Il17a* promoter and enhancer region. Consistent with [Figure 4B](#F4){ref-type="fig"}, REV-ERBα competed with RORγt for its shared RORE and/or RevRE in a concentration-dependent manner to regulate *Il17a+CNS5*-luciferase driven activity ([Figure 4C](#F4){ref-type="fig"}). The reduced repression observed with the DBD construct compared with the full-length REV-ERBα is likely due to its inability to recruit corepressor proteins, such as NCoR, via its LBD for active repression ([@R60]). Finally, in EL4 mouse T cell thymoma cells that endogenously expresses RORγt, we found that REV-ERBα competes with endogenous RORγt using the *Il17a+CNS5*-luciferase reporter ([Figure 4D](#F4){ref-type="fig"}).

To establish whether REV-ERBα modulates RORγt-mediated IL-17A expression in a DBD-dependent manner in T~H~17 cells, we retrovirally overexpressed empty vector, full-length REV-ERBα, REV-ERBα DBD, or REV-ERBα ΔDBD in T~H~17 cells and assessed IL-17A expression by flow cytometry. Both FL and REV-ERBα DBD significantly inhibited IL-17A protein expression, whereas IL-17A expression in the REV-ERBα ΔDBD condition was similar to the empty vector control ([Figure 4E](#F4){ref-type="fig"}). Finally, using an anti-REV-ERBα antibody ([@R7]), chromatin immunoprecipitation (ChIP) experiments in T~H~17 cells indicated that endogenous REV-ERBα was bound within the promoter and CNS5 region of the *Il17a* gene, suggesting that regulation of *Il17a* transcription is direct ([@R57]) ([Figure 4F](#F4){ref-type="fig"}). We also observed REV-ERBα bound within the upstream promoter region of *Rorc* ([@R40]) and *Nfil3* ([@R62]), which is consistent with published results; *Cry1* ([@R7]) and *Hprt* were used as positive and negative controls, respectively. These data indicate that REV-ERBα negatively regulates T~H~17 cell development by competing with RORγt at the RORE and/or RevRE sites, which includes the *Il17a* locus. Furthermore, an additional layer of regulation may occur through REV-ERBα-mediated repression of RORγt.

REV-ERBα-Specific Small Molecules Suppress T~H~17-Cell Development {#S8}
------------------------------------------------------------------

We previously developed and characterized SR9009, a proof-of-concept REV-ERB-specific synthetic ligand that demonstrated that the REV-ERBs could be pharmacologically targeted *in vivo* ([@R51]). Our efforts to improve SR9009 led to our identification of SR12418, which binds to both receptors in a time-resolved fluorescence resonance energy transfer (TR-FRET) biochemical assay and is more potent at REV-ERBα (half maximal inhibitory concentration \[IC~50~\] = 68 nM) and REV-ERBβ (IC~50~ = 119 nM) in a *Bmal1*-luciferase reporter assay than SR9009 ([Figures S4A--S4C, S5A, and S5B](#SD1){ref-type="supplementary-material"}) ([@R43]). SR12418 demonstrated significantly improved plasma exposure relative to SR9009 ([@R51]), was more effective at inhibiting IL-17A expression in EL4 cells, demonstrated specificity at the REV-ERBs, and did not exhibit activity at any other nuclear receptors ([Figures S5C--S5F](#SD1){ref-type="supplementary-material"}) ([@R51]). SR12418 also showed minimal off-target activity in a CEREP (Eurofins Scientific) panel screen of 84 G-protein coupled receptors, ion channels, and transporters (data not shown). Both SR9009 and SR12418 dose-dependently inhibited *Il17a* lucif-erase activity at REV-ERBα and REV-ERBβ and inhibited T~H~17 cell differentiation without affecting viability or other T helper populations (Figures [5A, 5B](#F5){ref-type="fig"}, [S6A, and S6B](#SD1){ref-type="supplementary-material"}). Expression of RORγt was also downregulated in drug-treated conditions relative to vehicle control ([Figure 5C](#F5){ref-type="fig"}). Quantitative real-time PCR analysis demonstrated that SR9009 and SR12418 potently repressed T~H~17-mediated gene expression and *Nfil3*, which is consistent with REV-ERBα acting as a repressor at RORE and/or RevRE sites ([Figure 5D](#F5){ref-type="fig"}). To establish whether REV-ERB-selective small molecules could override potent RORγt-driven T~H~17 differentiation, we retrovirally transduced naive CD4^+^ T cells with RORγt cultured under T~H~17-polarizing conditions and treated the cells with SR9009, SR12418, or vehicle control. Despite the potent and sustained ectopic RORγt expression, REV-ERB-selective small molecules were able to repress RORγt-mediated IL-17A expression ([Figure 5E](#F5){ref-type="fig"}). These data indicate that REV-ERB-selective small molecules can target the IL-17A pathway *in vitro* and override a potent RORγt stimulus.

Currently, RORγ modulators are being developed for the treatment of autoimmunity ([@R16]). However, RORγt is required for thymocyte survival ([@R28]; [@R52]), and one drawback of treatment with RORγ modulators is thymocyte apoptosis ([@R4]; [@R16]). To determine if REV-ERB ligands induced a similar pheno-type, we treated C57BL/6 mice for 3 days with SR2211 (a potent RORγ inverse agonist ([@R27]) (20 mg/kg, i.p., b.i.d.), SR9009 (100 mg/kg, intraperitoneal \[i.p.\], twice a day \[b.i.d.\]), SR12418 (50 mg/kg, i.p., b.i.d), or vehicle control. Although mice treated with SR2211 demonstrated reduced thymic cellularity, specifically in the double-positive stage, treatment with SR9009 or SR12418 did not display significant defects relative to vehicle control. ([Figure 5F](#F5){ref-type="fig"}). *Rorc*^*fl/fl*^ and *Rorc*^*fl/fl*^ × CD4 Cre mice were also analyzed as controls, and consistent with published reports, deletion of RORγ in the thymus leads to reduced cellularity and apoptosis in the double-positive stage ([@R28]; [@R52]). ([Figure S6C](#SD1){ref-type="supplementary-material"}). Thus, RORγ inverse agonists, such as SR2211, largely phenocopy the thymocyte apoptosis observed in RORγ knockout mice, whereas REV-ERB synthetic ligands do not.

REV-ERB-Selective Small Molecules Suppress T~H~17-Mediated Autoimmunity *In Vivo* {#S9}
---------------------------------------------------------------------------------

As proof of concept, we tested whether pharmacologically targeting the REV-ERBs *in vivo* would affect autoimmune disease course by immunizing C57BL/6 mice to induce EAE. Due to its superior pharmacological profile over SR9009, we focused on SR12418, which was administered daily (50 mg/kg, b.i.d.) versus vehicle control following immunization. Mice treated with SR12418 showed delayed onset and severity of disease compared to the vehicle-control-treated group ([Figure 6A](#F6){ref-type="fig"}). The incidence of disease was greatly diminished in the SR12418 treated group, with approximately 20% of mice developing overt signs of disease compared to 90% of vehicle-control mice. SR12418 treatment did not demonstrate overt signs of toxicity, as the weight of the animals remained relatively constant throughout the experiment. Evaluation of liver demonstrated that SR12418 did not appear to significantly perturb the circadian rhythm in other tissues evaluated ([Figure S7A](#SD1){ref-type="supplementary-material"}). Evaluation of the draining LNs and CNS indicated a reduction in the frequency and number of CD3^+^CD4^+^ T cells at the peak of disease ([Figure 6B](#F6){ref-type="fig"}). Intracellular fluorescence-activated cell sorting (FACS) analysis demonstrated a significantly decreased frequency and number of RORγt^+^ cells in the LNs and CNS of the SR12418-treated mice relative to vehicle controls ([Figure 6D](#F6){ref-type="fig"}). The absolute number of GM-CSF^+^ T cells was significantly lower in the SR12418 treated mice as was the frequency and number of IL-17A^+^ and pathogenic IL-17A^+^IFNγ^+^ cells in the LNs and CNS than mice receiving vehicle control ([Figures 6C and 6E](#F6){ref-type="fig"}). Thus, targeted pharmacological modulation of REV-ERB activity *in vivo* effectively suppresses the development and progression of T~H~17-driven EAE.

To further evaluate the therapeutic efficacy of SR12418, we first performed intervention studies utilizing the adoptive T cell transfer model of colitis ([@R24]; [@R34]) ([Figure 7A](#F7){ref-type="fig"}). Following procedures described above, at 3-weeks after T cell transfer, SR12418 (50 mg/kg, b.i.d.) or vehicle control was administered twice daily for the duration of the experiment. PBS was used as a control. Neither group displayed any overt difference in body weight, colon weight, colon length, or colon weight/length ratio over time ([Figure S7B](#SD1){ref-type="supplementary-material"}). However, FACS analysis of colon tissue revealed that SR12418 led to a reduction in the frequency of a4b7^+^ T cells relative to vehicle controls, suggesting SR12418 hampered the ability of the T cells to home to the intestines ([Figure 7B](#F7){ref-type="fig"}). Intracellular FACS analysis demonstrated a decreased frequency of RORγt^+^ ells in the colons of the SR12418-treated mice relative to vehicle controls, whereas the frequency of IL-17A^+^ and pathogenic IL-17A^+^IFNγ^+^ cells was also lower than mice receiving vehicle control ([Figures 7C and 7D](#F7){ref-type="fig"}). Interestingly, the frequency of CD25^+^Foxp3^+^ Tregs was significantly increased in the colons of SR12418-treated mice relative to the vehicle controls ([Figure 7E](#F7){ref-type="fig"}).

We next tested the therapeutic capacity of SR12418 for treating ongoing PLP139--151-induced relapsing-remitting EAE (R-EAE) in SJL/J mice. SR12418 (50 mg/kg, b.i.d.) or vehicle control was administered twice daily once mice had recovered from the first wave of disease (day 18 post-immunization). SR12418 resulted in a significant reduction in the relapse severity compared to the animals receiving vehicle control ([Figure 7F](#F7){ref-type="fig"}). Twelve of the 17 mice in the vehicle-treated group relapsed, with the average maximum relapsing clinical score for each mouse recorded between 2.5 and 3.5. In contrast, only 5 of the 17 SR12418-treated animals relapsed, with the maximum clinical score recorded as no greater than 1. FACS analysis of the CNS from the animals revealed a significant decrease in the frequency and number of CD4^+^ and CD8^+^ effector cells (CD44^hi^) in the SR12418-treated animals versus vehicle control ([Figure 7G](#F7){ref-type="fig"}), which may be attributed to a decreased frequency and number of CD4^+^CCR6^+^ T cells in the CNS ([Figure 7H](#F7){ref-type="fig"}). Intracellular FACS analysis demonstrated a decreased frequency and number of RORγt^+^ cells in the CNS of the SR12418-treated mice relative to vehicle controls, whereas the number of RORγt^+^GM-CSF^+^ cells was also decreased ([Figures 7I and 7J](#F7){ref-type="fig"}). Finally, SR12418-treated animals demonstrated a decreased frequency of IL-17A^+^ cells and decreased number of IL-17A^+^ and pathogenic IL-17A^+^IFNγ^+^ cells in CNS compared to mice receiving the vehicle control ([Figure 7K](#F7){ref-type="fig"}). These results offer proof-of-concept that pharmacological modulation of REV-ERB activity post-disease onset can suppress the progression of T~H~17-driven autoimmunity and chronic inflammatory disorders.

DISCUSSION {#S10}
==========

In this study, we demonstrated that REV-ERBα is induced exclusively in T~H~17 cells and acts as a cell-intrinsic negative regulator of proinflammatory T~H~17-cell function. Our results suggest that the induction of REV-ERBα represents a previously undefined and critical checkpoint during T~H~17 cell development. Overexpression of REV-ERBα inhibited T~H~17 cell development whereas its deletion led to increased proinflammatory cytokine production *in vitro* and *in vivo*, which is consistent with its role as a repressor of gene transcription ([@R25]). Mechanistically, REV-ERBα competes with RORγt for binding to the same RORE and/or RevRE genomic response sequence at the *Il17a* locus, which was further supported by the overlap in gene signatures between WT/KO and WT/RORγt^−/−^ T~H~17 cells. REV-ERBα bound upstream of the *Rorc* transcriptional start site, suggesting it also regulated T~H~17 cell development through repression of RORγt itself. Finally, REV-ERB-specific small molecules suppressed T~H~17 cell development *in vitro* and were extremely effective when used prophylactically in suppressing T~H~17-mediated autoimmunity *in vivo*. Importantly, SR12418 was effective when used in a therapeutic mode in two separate models of T~H~17-mediated inflammatory diseases, colitis, and EAE. Collectively, these findings demonstrate that the nuclear receptor REV-ERBα is a cell-intrinsic negative regulator of T~H~17 cell development whose activity is critical for dampening proinflammatory cytokine production.

Although cross-talk between the RORs and REV-ERBs is well established in the regulation of the circadian rhythm and metabolic processes, cross-talk between these receptors has not been extensively explored in the immune system. Here, we demonstrate that REV-ERBα competes with RORγt at their shared RORE and/or RevRE sites, including the *Il17a* locus to regulate IL-17A cytokine expression. Comparison of the KO and ROR0γ^−/−^ T~H~17 cell RNA sequencing (RNA-seq) datasets suggests there is overlap in the genes that have clear RORE and/or RevREs in their promoter regions, including *Il17f*, *Ccl20*, and *Ltb4r1*. Although many genes did not overlap with the RORγ^−/−^ T~H~17 cells, many of these were downregulated in KO T~H~17 cells, likely indicating that REV-ERBα was indirectly regulating those genes. Of the other non-RORγ overlapping genes that were upregulated in KO T~H~17 cells, these repressive effects could be a function of DNA-independent mechanisms, otherwise known as tethering, in which REV-ERBα binds to cell-type-specific transcription factors to negatively regulate gene transcription to convey a tissue-specific genetic program tailored to the needs of that cell type ([@R64]). In metabolic tissues such as the liver, these two different modes of repression enable REV-ERBα the ability to stabilize the circadian oscillations of clock genes at RORE and/or RevREs while coupling metabolism to environmental and metabolic changes ([@R64]). Perhaps a comparable phenomenon endows REV-ERBα the ability to function in a similar manner in T~H~17 cells. More in-depth ChIP and ChIP sequencing studies will need to be performed to establish these different modes of REV-ERB-mediated repression.

REV-ERBα also appears to regulate the expression of RORγt, and although consistent with previously published work ([@R7]; [@R40]), we do not believe the majority of effects observed *in vitro* and *in vivo* on T~H~17 cell function, including IL-17A expression, are due to REV-ERBα-dependent effects on RORγt expression. Mechanistically, binding of REV-ERBα upstream of *Rorc* would negatively regulate RORγt expression and, in turn, indirectly regulate IL-17A expression *in vitro* and *in vivo*. Therefore, the loss of REV-ERBα would have the opposite effect, and one could argue that this would be the sole mechanism for REV-ERBα-mediated regulation of T~H~17 cell development. However, decreased IL-17A expression was also observed when RORγt was ectopically overexpressed in T~H~17 cells and REV-ERB-specific small molecules were added to the culture. Since the expression of RORγt is driven by a retroviral element, REV-ERBα could not regulate RORγt at this level. Thus, our data indicate a level of complexity to the cross-talk between the RORs and REV-ERBs in T~H~17 cell development that extends beyond simple competition for DNA response elements. At one level, RORγt and REV-ERBα compete for binding at the *Il17a* locus to contain the inflammatory response. At another level, the RORs and REV-ERBα drive and inhibit each other's expression ([@R48]; [@R54]), with the RORs potentially driving REV-ERBα expression upon development in order for REV-ERBα to limit not only cytokine expression but also expression of RORγt itself to help temper T~H~17 proinflammatory responses.

Our observations that REV-ERBα acts as a potent negative regulator of proinflammatory T~H~17 cell development and auto-immunity contradicts a previous study by [@R62] where they demonstrated that REV-ERBα functionally repressed *Nfil3*, which, in turn, repressed RORγt to regulate *Il17a* expression and T~H~17 cell development, indicating an indirect role for REV-ERBα in the regulation of T~H~17 cell development. In the study by [@R62], KO mice presented with decreased IL-17A expression *in vitro* and *in vivo*, and although the different gut flora compositions between the facilities could be a factor affecting the development of T~H~17 cells ([@R30]; [@R35]; [@R58]), or the use of different REV-ERBα KO strains ([@R8]; [@R46]), it is important to note that the studies performed by [@R62] were largely in naive mice with the purpose of elucidating the diurnal regulation of T~H~17 cell function *in vivo*. In that setting, REV-ERBα and NFIL3 cooperatively regulated T~H~17 cells in the gut in a clock-dependent manner ([@R62]). In contrast, our work was performed under specific autoimmune- or chronic proinflammatory-inducing conditions, which are known to be T~H~17 driven, to specifically address the role of REV-ERBα outside of its function as a core clock component. Under the types of stressors used in our study here, REV-ERBα is required to restrain proinflammatory responses, and in the absence of REV-ERBα, aberrant T~H~17 responses and autoimmunity ensue. Supporting this notion, microarray analysis of CNS tissues ([@R44]), RNA-sequencing of spinal cords ([@R49]), and mRNA analysis of CNS ([@R53]) from mice with active EAE all demonstrate a significant decrease in REV-ERBα expression. These data correlate with the findings from our EAE experiments, wherein the loss of REV-ERBα exacerbates EAE, and enhanced REV-ERB activity, through use small molecules agonists (SR9009 or SR12418), suppresses EAE. Additionally, we showed that T cell-specific loss of REV-ERBα exacerbated the development of colitis, further supporting the notion that REV-ERBα acts as a critical negative regulator of proinflammatory T~H~17-mediated responses.

Despite the *in vivo* differences between our study and [@R62], we did observe REV-ERB-mediated effects on *Nfil3* in T~H~17 cells, which was likely a function of REV-ERBα binding at the *Nfil3* promoter region. However, the effects do not appear to be sufficient to override the direct effects of REV-ERBα at *Il17a* or RORγt itself, as we observed reduced IL-17A expression in REV-ERBα-overexpressing cells and cells treated with a synthetic REV-ERB ligand. Interestingly, despite the increased expression of *Nfil3* in KO T~H~17 cells, we still observed an increased expression of RORγt and IL-17A ([@R62]). This could be a function of protein degradation because NFIL3 has been shown to be post-translationally modified and targeted for proteasomal degradation in a CK1ε-dependent manner ([@R10]). However, overexpression and knock down of *Nfil3* also had little effect on IL-17A expression, which is consistent with a previous study ([@R9]) finding that retroviral transduction of *Nfil3* did not significantly affect T~H~17 cell development. This conflicting *in vitro* data could be due to differences in cell culture conditions, reagents, or transduction protocols. Clearly the network linking REV-ERBα and NFIL3 in T~H~17 cells is complex and further work is needed to elucidate the interplay between these transcription factors in proinflammatory T~H~17 cell development. Overall, our data provide a new perspective on REV-ERBα, revealing its negative regulatory role of proinflammatory T~H~17-mediated immune responses.

Modulation of nuclear receptor activity has proven to be a powerful and effective means to treat a host of diseases ([@R36]). We have developed and described several REV-ERB-specific small molecules exhibiting various degrees of *in vivo* exposure ([@R51]). Using these small molecules, we demonstrated that REV-ERB agonism is sufficient to inhibit T~H~17 cell development *in vitro* by inhibiting T~H~17-specific genes (e.g., *Il17a*, *Il22*, and *Il23r*) as well as RORγt expression, which is consistent with our genetic experiments. Furthermore, REV-ERB-specific small molecules also inhibit the development of T~H~17 cells *in vivo*, ameliorating the signs and incidence of EAE, a T~H~17-mediated autoimmune disease. Importantly, REV-ERB-specific small molecules are efficacious when used therapeutically, blocking the development of colitis and preventing disease relapse in a relapsing-remitting model of multiple sclerosis. It is possible that some of the *in vivo* effects observed with SR12418 are a function of systemic exposure, which would target the REV-ERBs in other tissues, including macrophages, which have been demonstrated to express the REV-ERBs and can act as antigen-presenting cells ([@R11]; [@R15]; [@R29]). Additionally, SR12418 and SR9009 target both REV-ERBα and REV-ERBβ, and although the focus of this work was on REV-ERBα, our data do not rule out effects on REV-ERBβ. In fact, REV-ERBβ is differentially expressed in T~H~17 cells, and its overexpression did inhibit T~H~17-mediated cytokine expression, but it was not as potent as REV-ERBα. Thus, the combined deletion of both REV-ERBs may have a more exacerbated effect *in vivo* on disease course. By this logic, it would stand to reason that ligands that target both REV-ERBs would also have a greater repressive effect than a ligand that targeted only a single receptor subtype.

In summary, we demonstrate here that the nuclear receptor REV-ERBα is a critical, cell-intrinsic negative regulator of proinflammatory T~H~17-mediated autoimmunity, competing with RORγt at their shared target gene sequences, of which *Il17a* is one. Although there is still much work to be done to fully elucidate the function of REV-ERBα in T~H~17 cells, our work also demonstrates the therapeutic potential for targeting REV-ERBα for the treatment of T~H~17-mediated autoimmune disorders. Currently, there is a massive pharmaceutical effort to develop RORγ-selective inverse agonists for the treatment of T~H~17-mediated disorders. However, these RORγ synthetic ligands pheno-copy *Rorc*^−*/*−^ mice by rapidly inducing thymic apoptosis, whereas REV-ERB ligands do not. Our data indicate that the use of REV-ERB-specific small molecules may be an effective, alternative approach to treat T~H~17-mediated diseases.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S14}
--------------------------------------

### Animals {#S15}

The following mouse strains used were purchased from the Jackson Laboratory and/or were bred at Scripps Research - (Florida). C57BL/6J (B6); SJL/J, B6.Cg-*Nr1d1*^*tm1Ven*^/LazJ (KO) ([@R8]); B6.129S7-*Rag1*^*tm1Mom*^/J (*Rag1*^−*/*−^) ([@R39]); B6(Cg)-*Rorc*^*tm3Litt/J*^ (*Rorc*^*fl/fl*^) ([@R22]); Tg(Cd4-cre)1Cwi/BfluJ (CD4 Cre). *Rorc*^*fl/fl*^ mice were crossed with CD4 Cre mice to generate *RORc*^*fl/fl*^ × CD4 Cre mice. All experiments were conducted at controlled temperature (22--23°C), humidity \~60%, and 12h:12h light:dark cycles. Mice had access to regular chow (Harlan 2920X) and water, *ad libitum*. For all *in vitro* experiments, both male and female mice (8--10 weeks old) were sacrificed between 8 and 10am. For all *in vivo* experiments, 7--10 week-old male and female mice were used, and were sacrificed between 7 and 11am. For EAE experiments, mice were immunized between 11am and 1pm. The specific age and sex of the mice for experiments is described under each model's details below. All mice were maintained under specific pathogen free conditions. All studies conform to and were approved by the Institutional Animal Care and Use Committee (IACUC) at the Scripps Research Institute (Florida).

### Cell lines {#S16}

HEK293 (female), EL4 (unknown), and Plat-E (female) cells were cultured in DMEM supplemented with 10% FBS, 2mm L-glutamine, and 1% penicillin/streptomycin at 37°C, 5% CO~2~ under standard culture conditions. Lymphocytes were cultured in IMDM medium with 10% FBS, 100IU/mL penicillin, 100 μg/ml streptomycin, 50uM β-mercaptoethanol, and 2mm L-glutamine. The gender of EL4 cells is unavailable at this time.

METHOD DETAILS {#S17}
--------------

### Chemical synthesis and reagents {#S18}

SR9009 has been previously described ([@R51]). Synthesis of SR12418 is as follows:

(*S*)-(3-((4-(tert-Butoxy)phenoxy)methyl)-6-fluoro-3,4-dihydroisoquinolin-2(1*H*)-yl)(naphthalen-1-yl)methanone

#### Step 1: (S)-3-carboxy-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-ium chloride {#S19}

To a suspension of 3-fluoro-*L*-phenylalanine (10.0 g, 55.4 mmol) in conc. HCl (50 mL) was added aq. formaldehyde solution (37% wt.; 6.2 mL, 83.3 mmol). The reaction mixture was heated to 90°C and stirred for 5 h and the completion of the reaction was monitored by anal. HPLC. The mixture was then cooled to room temperature and filtered to give the title compound as the HCl salt (10.8 g, 84% yield), which was used without further purification. ^1^H NMR (400 MHz, d-DMSO) δ 14.17 (broad S, 1H), 10.12 (broad S, 2H), 7.37--7.22 (m, 1H), 7.20--7.13 (m, 2H), 4.45--4.41 (m, 1H), 4.33 (m, 2H), 3.37 (dd, J = 16 Hz, 4.8Hz), 3.22--3.15 (m, 1H); ^13^C NMR (100 MHz, d-DMSO) 169.6, 161.1 (d, J = 242 Hz), 133.5 (d, J = 8.2 Hz), 128.6 (d, J = 8.4 Hz), 124.6 (J = 2.7 Hz), 115.0 (d, J = 21.8 Hz), 114.1(d, J = 21.8 Hz), 52.6, 43.2 and 28.0; ^19^F NMR (376.5 MHz, DMSO-d~6~) δ −115.19, −119.13; MS (ESI) 196.1 (M + H).

#### Step 2: (S)-6-fluoro-3-(hydroxymethyl)-1,2,3,4-tetrahydroisoquinolin-2-ium chloride {#S20}

BH~3~.DMS (8.1 mL, 85.6 mmol) was added slowly to ((S)-3-carboxy-6-fluoro-1,2,3,4-tetrahydroisoquinolin-2-ium chloride (6.6 g, 28.5 mmol) and anhydrous THF (60 mL) at RT under argon. The mixture was then heated to 70°C for 3h monitoring the reaction by analytical HPLC. When the starting material was consumed, the reaction was cooled to RT and the reaction was quenched with THF/water (1:1) followed by dilute HCl (2M, 50 mL). The mixture was heated to 80°C for 3h and then cooled and concentrated to obtain the title compound as the HCl salt, which was used without further purification. ^1^H NMR (400 MHz, d-DMSO) δ 9.88 (broad S, 1H), 9.61 (broad S, 1H), 7.36--7.32 (m, 1H), 7.15--7.10 (m, 2H), 5.61 (broad s, 1H), 4.27 (s, 2H), 3.84--3.68 (m, 2H), 3.51 (broad s, 1H), 3.0 (d, J = 8.0 Hz); ^13^C NMR (100 MHz, d-DMSO) 161.1 (d, J = 242 Hz), 134.4 (d, J = 8.1 Hz), 128.6 (d, J = 8.4 Hz), 125.0 (J = 2.8 Hz), 115.0 (d, J = 21.3 Hz), 113.7 (d, J = 21.5 Hz), 60.4, 53.8, 43.3 and 27.4; ^19^F NMR (376.5 MHz, DMSO-d~6~) d 115.24, 119.22; MS 182 (M + (ESI) H).

#### Step 3: (S)-(6-Fluoro-3-(hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl)(naphthalen-1-yl)methanone {#S21}

To a mixture of the above crude (S)-6-fluoro-3-(hydroxymethyl)-1,2,3,4-tetrahydroisoquinolin-2-ium chloride (28.5 mmol) in CH~2~Cl~2~ (100 mL) and NaHCO~3~ (12 g, 142.6 mmol) was slowly added 1-naphthoyl chloride (4.71 mL, 31.4 mmol). The reaction was stirred at RT overnight. Water was added and the layers were separated. The aqueous layer was extracted with CH~2~Cl~2~ (2×150 mL). The combined organic layers were washed with brine, dried (Na~2~SO~4~), and concentrated. The resulting crude residue was purified by chromatography on silica gel (EtOAc/hexanes) to afford the title compound (6.94 g, 73% yield by 2 steps). ^1^H NMR (400 MHz, d-DMSO) δ 8.06--6.88 (m, 10H), 5.52--5.10 (m, 1H), 4.44--2.77 (m, 7H); MS (ESI) 336 (M + H).

#### Step 4: (S)-(3-((4-(tert-Butoxy)phenoxy)methyl)-6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)(naphthalen-1-yl)methanone {#S22}

To the solution of (S)-(6-fluoro-3-(hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl)(naphthalen-1-yl)methanone (5.19 g, 15.5 mmol), 4-(tert-butoxy)phenol (2.83 g, 17.0 mmol) and n-Bu~3~P (7.6 mL, 31.0 mml) in anhydrous THF (100mL) under argon was added dropwise 1,1'-(azodicarbonyl)dipiperidine (ADDP) (7.8 g, 31.0 mmol) in anhydrous THF (70 mL). The reaction was stirred at RT overnight and the completion of the reaction was monitored by analytical HPLC. The precipitate was filtered and washed with hexane. The resulting filtrate was concentrated *in vacuo* to give the crude product which was purified by chromatography on silica gel (EtOAc/hex) to afford the title compound as a colorless solid (5.2 g, 69% yield); ^1^H NMR (400 MHz, CDCl3) δ 8.08--6.41 (m, 14H), 5.71--5.51 (m, 1H), 4.46--4.15 (m, 2H), 3.91--3.61 (m, 2H), 3.10--3.02 (m, 2H), 1.33--1.25 (m, 9H); ^19^F NMR (376.5 MHz, CDCl~3~) δ −114.88, −114.93, −115.55, −115.57; HRMS (ES+): m/z called for C~31~H~30~FNO~3~ \[M+H\]: 484.2210; found 484.2294.

### Induction and clinical evaluation of EAE {#S23}

Chronic, MOG-induced EAE was induced in 10-week-old, female WT or KO mice by subcutaneous (s.c.) injections over two sites in the flank with 150mg per mouse of MOG35--55 peptide in an emulsion with CFA supplemented with 2.25 μg/ml *Mycobacterium tuberculosis*, strain H37Ra (500ug per mouse). Pertussis toxin was dissolved in PBS and injected i.p. at 200 ng per mouse 3 hr post immunization (Day 0) and 24 h later. For chronic, MOG-induced drug treatment experiments, 10-week-old, female B6 mice were immunized using EAE induction kits according to manufacturer's instructions. For R-EAE, 10-week old, female SJL/J mice were immunized using EAE induction kits according to manufacturer's instructions. Mice were scored daily on a scale of 0--5 in a double-blinded manner using the following criteria: 0, no clinical disease; 1, limp/flaccid tail; 2, limp tail and hind leg weakness; 3, limp tail and complete paralysis of hind limbs; 4, limp tail, complete hind limb and partial front limb paralysis; 5, quadriplegia or pre-moribund state. Gradations of 0.5 were used when mice exhibited signs that fell between two scores. For drug treatment experiments, SR12418 was dissolved in a 10% DMSO, 10% Tween 80, and 80% H~2~O solution equaling 5μg/ml and administered intraperitoneally (i.p.) at 50mg/kg as was vehicle control (10% DMSO, 10% Tween 80, and 80% H2O) twice per day (b.i.d). The treatment was started the evening of the immunization (MOG-EAE), or once the animals recovered from the first wave of disease (R-EAE) and continued for the duration of the experiment. For all b.i.d. dosing, animals were dosed at 7am and 7pm (lights on/lights off). At the termination of the experiment T cells were isolated from brain and spinal cord following perfusion of deeply anesthetized mice with cold PBS. CNS was minced before being passed through a 70um mesh cell strainer. Single cell suspensions were centrifuged and resuspended in 37% percoll. After further centrifugation, supernatant was removed and the pelleted mononuclear cells were washed and used for staining.

### T cell-transfer colitis model {#S24}

Spleens were collected from 8- to 10-week-old, female KO or control (WT) mice in order to sort naive CD4^+^ T cells. 5 × 10^5^ CD4^+^CD25^−^CD62L^hi^CD44^lo^ cells suspended in PBS were adoptively transferred i.p. (100ul/mouse) into 8-week-old, female *Rag1*^−/−^ recipient mice and monitored bi-weekly for body weight change. Beddings were routinely transferred between cages to distribute microflora and limit bias between cages regarding disease development. For drug treatment experiments, vehicle or SR12418 was administered starting at three-weeks post T cell transfer and continued for the duration of the experiment following procedures and time points described in the EAE experiments above. Mice were sacrificed to assess histological inflammation due to ethical requirements if they reached 80% or less of their original body weight. At the termination of the experiment, the whole colon and ileum (distal 1/3 part of the small intestine) were removed from the mouse. Colon length was measured first before each segment of the intestine was opened longitudinally and the fecal contents gently removed. Next, colon weights were measured prior to dissection longitudinally into two sections. One of the sections was rolled (Swiss roll) from the rectum along with the ileum and fixed in 10% neutral buffered formalin for 24 h. Swiss roll samples were then embedded in paraffin wax and sectioned for histological examination and immunohistochemistry staining. The other section of the colon was dissected in equal halves, designated as 'proximal' and 'distal' colon and snap frozen in dry ice for RNA analysis. [*Histological Assessment of colon*]{.ul} - following overnight formalin fixation, paraffin-embedding, and standard H&E staining, histological colitis scoring of H&E-stained sections was performed blinded. Assessments of crypt architecture, crypt abscesses, tissue damage, goblet cell depletion, inflammatory cell infiltration, and neutrophil counts were assigned scores with the maximum combined score for each part of the intestine equaling 25([@R56]). For cell isolation - whole colons were removed, flushed with PBS to remove fecal contents, and opened longitudinally. Tissues were cut into small segments and incubated for 30 min at room temperature in DMEM without phenol red plus 0.15% DTT. After washing with media, intestines were incubated for 30 min at room temperature in media containing 1 mm EDTA to remove the epithelium. After washing again with media, [lamina propria]{.ul} was digested in media containing 0.25 μg/ml liberase TL and 10 U/mL RNase-free DNaseI in a bacterial incubator for 15--25 min at 37°C. Single cell suspensions were passed through 70 mm mesh cell strainer and [mononuclear cells]{.ul} were isolated by 70/30% percoll gradient centrifugation. Monocuclear cells were washed two more times, counted, and used for FACS analysis.

### Analysis of thymocytes {#S25}

For the measurement of DP survival kinetics, male, 7--9 week-old, male C57BL/6 mice were treated with vehicle control or compounds for 3 days. All compounds were formulated in 15% cremophor at the following concentrations unless otherwise noted: SR2211 -- 2μg/ml; SR9009 -- 10μg/ml; SR12418 -- 5μg/ml, and administered i.p., b.i.d. At the termination of the experiment, thymii were collected, minced, and passed through a 70um mesh cell strainer. Cell counts were performed prior to staining the cells for flow cytometry analysis.

### *In vitro* CD4^+^ T cell differentiation {#S26}

Naive CD4^+^ T cells from spleen and LNs of 8--10-week-old male and female mice were purified after removing the red blood cells using Lympholyte-M solution. Cells were enriched for naive CD4^+^ T cells using the mouse naive CD4^+^ T Cell Isolation Kit according to the manufacturer's instruction. If sorting was performed (FACS Aria II; BD Bioscience), the CD4^+^CD25^−^CD62L^hi^CD44^lo^ fraction was collected. The conditions for the different T~H~ cell subsets were: For T~H~0 (neutral conditions): 5 μg/ml anti-IL-4 and 5 μg/ml anti-IFNγ; For T~H~1 conditions: 5 μg/ml anti-IL-4, 20 ng/ml IL-12 and 10ng/ml IFNγ; For T~H~2 conditions: 5 μg/ml anti-IFNγ and 10ng/ml IL-4; For T~H~17 conditions: 5 μg/ml anti-IFNγ, 5 μg/ml anti-IL-4, 1.5ng/ml TGFβ and 30ng/ml IL-6; For iT~reg~ conditions: 5 μg/ml anti-IFNγ, 5 μg/ml anti-IL-4, and 5ng/ml TGFβ. Other cytokines used for various T~H~17 conditions: IL-1b (10ng/ml), IL-21 (20ng/ml), and IL-23 (20ng/ml). 1 × 10^6^ cells/ml of naive CD4^+^ T cells were activated with anti-CD3 and anti-CD28 by precoating plates with 100 μg/ml goat anti-hamster IgG. After 48 h, cells were removed from the TCR signal and recultured at a concentration of 1 × 10^6^cells/ml. Four days after activation, all cells were restimulated with 50ng/mL phorbol-12-myristate-13-acetate (PMA)and 1 μg/ml ionomycin for 2 hr with the addition of GolgiStop for an additional 2 hr before intracellular staining. Cells were cultured in IMDM medium with 10% FBS, 100IU/mL penicillin, 100 μg/ml streptomycin, 50uM β-mercaptoethanol, and 2mm L-glutamine. All cultures were performed in a volume of 200ul in 96-well U-bottomed plates.

### Flow cytometry {#S27}

[Surface staining]{.ul}: single cell suspensions prepared from spleen, LNs, colons, CNS, etc. were washed and stained with fluorescenceconjugated antibodies for 20 min, washed, then resuspended in FACS buffer (0.5% BSA, 2mm EDTA in PBS). [Intracellular cytokine staining]{.ul}: cells were re-stimulated with 50ng/mL PMA and 1 μg/ml ionomycin for 2 hr with the addition of GolgiStop for an additional 2 hr. Cells were then surface stained using procedures outlined above, fixed and permeabilized using the Foxp3 staining kit. Flow cytometric analysis was performed on a BD LSRII (BD Biosciences) instrument and analyzed using FlowJo software.

### Retroviral Transduction {#S28}

To generate murine REV-ERBα or REV-ERBβ retroviral vectors, mouse REV-ERB sequences were inserted into the MIGR1 vector using the XhoI site and further screened for orientation. The DBD truncation construct was generated by PCR amplification of residues 103--225 of REV-ERBα with addition of 5^′^ XhoI and 3^′^ HpaI cut sites. The amplified product was cloned into the MIGR1 vector by double digest followed by T4 DNA ligation. The ΔDBD deletion construct was generated by a single PCR reaction of the MIGR1-REV-ERBα construct to delete residues 132--197. To generate the murine NFIL3 retroviral vector, the mouse NFIL3 sequence was inserted into the MIGR1 vector using the XhoI and BamHI sites. In each experiment, MIGR1 empty vector was used as a control. shRNAmirs against mouse CD8 (Cd8a) and *Nfil3* were purchased from TransOMIC Technologies. shRNAmirs were PCR amplified and cloned into ametrine-expressing murine retroviral vectors (LMPd) containing the enhanced miR-30 cassette([@R13]). MIGR1 RORγt retroviral construct was a gift from Dan Littman (Addgene Plasmid \#24069). [Virus production]{.ul}: Plat-E cells were cultured in DMEM containing 10% fetal bovine serum, 2mm L-glutamine, and 1% penicillin/streptomycin at 37°C under standard culture conditions. Plat-E cells were seeded at 350,000 cells/ml in a 6 well plate the day before transfection. 3 mg total retroviral plasmid DNA (1.5 μg MIGR1 plus 1.5 μg pCL-Eco) was transfected using Fugene6 reagent according to manufacturer's protocol. Viral supernatant was harvested 48 hr post transfection and used immediately for transduction. For [retroviral transduction]{.ul}, naive CD4^+^ T cells were stimulated as indicated with anti-CD3 and anti-CD28 and cultured under T~H~17 conditions. At 24 h post TCR priming, the culture medium was replaced with virus supplemented with 8 μg/ml polybrene. Plates were centrifuged at 1,800 rpm for 90 h at 37°C and then incubated at 37°C for 3--4 h. After this time, the medium was replaced with the original media removed before addition of virus.

### Luciferase reporter assays {#S29}

HEK293 cells were plated 24 hr prior to transfection in 96-well plates at a density of 15 × 10^3^ cells/well. Transfections were performed using Lipofectamine 3000 according to manufacturer's protocol. To generate the DBD REV-ERBα truncation construct, residues 103--224 of the human REV-ERBα were cloned into the pcDNA3.1+ plasmid by HindIII and BamHI double digest. The ΔDBD deletion construct in was generated by PCR deletion of residues 131--197 of pcDNA3.1+ REV-ERBα. For drug treatments - 16 hr post-transfection, cells were treated with vehicle or compound. 24 hr post-treatment luciferase activity was measured using BriteLite and read using an Envision multilabel plate reader (PerkinElmer Life and Analytical Sciences). All values were normalized to DMSO to produce fold induction values. For assays in which drug treatment did not occur, luciferase activity was measured 24h post-transfection by DualGlo firefly and renilla luciferase reagents. Mouse EL4 cells were transfected using the Amaxa cell line nucleofector kit L according to manufacturer's instructions. 6 hr post-nucleofection, EL4 cells were stimulated with PMA (50ng/ml) and ionomycin (1ug/ml), plated in 12 well plates and incubated overnight for 16 hr. The following day, luciferase activity was measured as indicated for HEK293 cells. The pGL4 mIl17a-2kb promoter + CNS5 was a gift from Warren Strober ([@R63]). The pGL3 mBmal1 luciferase reporter has been previously described ([@R51]; [@R61]).

### ChIP {#S30}

ChIP assays were performed following manufacturer's instructions. Briefly, naive CD4^+^ T cells were differentiated under T~H~17 conditions for 3 days, fixed in 1% formaldehyde for 10 min at room temperature, quenched in glycine (120mm) on ice for 5 min, and washed with PBS prior to lysis. Chromatin (20 × 10^6^ cells/condition) was sheared with a Misonix S-4000 sonicator for 20 × 10 s cycles at 20% amplitude to yield 100--300 bp DNA fragments. After removing 1% as input DNA, immunoprecipitation was performed by adding anti-REV-ERBα antibody ([@R7]) (4ug/reaction) along with protein G magnetic beads on an end-to-end rotator at 4°C overnight. KO T~H~17 cells and rabbit IgG were used as negative controls. Beads were then washed 3X with low salt ChIP buffer, followed by high salt ChIP buffer and eluted by re-suspending the beads in Elution Buffer. Both input and ChIP DNA were then incubated at 65 C for 30 min, followed by addition of Proteinase K and incubated at 65°C to reverse crosslink for 2 hr. DNA was then purified with QIAquick columns per manufacturer's instructions and resuspended in a 50 mL volume. Real-time PCR detection of immunoprecipitated targets was performed using SYBR Green including passive reference dye (ROX) on a HT7900 Fast Real Time PCR system (Life Technologies, CA). A standard curve was generated for each sample based on amplification of serial dilutions of input DNA. ChIP DNA PCR reactions were performed in duplicates. Melt curves were analyzed to ensure amplification of specific target sequences. The primers used for qRT-PCR can be found in [Table S3](#SD1){ref-type="supplementary-material"}.

### Quantitative real-time PCR {#S31}

For *in vitro* cultures, total RNA was extracted using a RNeasy Plus Micro Kit and reverse transcribed using iScript cDNA biosynthesis kit. Tissue samples (snap frozen and homogenized) - following isolation using TRIzol reagent mRNA was purified using RNeasy columns, followed by cDNA synthesis using iScript containing oligo (dT) and random hexamer primers. Real-time PCR was performed using SYBR Green including passive reference dye on a HT7900 Fast Real Time PCR system (Life Technologies, CA). All gene expression data were normalized to the housekeeping gene, b*-actin* unless otherwise mentioned, using a DD cycle threshold-based algorithm followed by fold change comparison with the average of the control group. Primer efficiencies were determined using complementary DNA and primer dilutions for each gene of interest. Primers sequences for specific genes are provided in [Table S3](#SD1){ref-type="supplementary-material"}.

### RNA-sequencing and data analysis {#S32}

mRNA was extracted from T~H~17 cells on Day 2 (WT versus REV-ERBα KO cells) or Day 3 (MIGR1 transduced cells) of *in vitro* differentiation. Total RNA was extracted using QIAGEN RNeasy kits, quantified using the Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA), and run on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) for quality assessment. DNase-treated total RNA (300ng) was depleted of ribosomal RNA (rRNA) using appropriate probes provided by Illumina and further assessed on the bio-analyzer to confirm 18S and 28S rRNA peaks are depleted. rRNA-depleted RNA is processed using the TruSeq Stranded Total RNA sample prep kit. Briefly, RNA samples are chemically fragmented in a buffer containing divalent cations and heating at 94°C for 8 min. The fragmented RNA is random hexamer primed and reverse transcribed to generate first strand cDNA. The second strand is synthesized after removing the RNA template and incorporating dUTP in place of dTTP. cDNA is then end repaired and adenylated at their 3^′^ ends. A corresponding 'T' nucleotide on the adaptors is utilized for ligating the adaptor sequences to the cDNA. The adaptor ligated DNA is purified using magnetic Ampure XP beads and PCR amplified using 12--13 cycles to generate the final libraries. The final libraries are size selected and purified using 1.0 × Ampure XP beads to remove any primer dimers. The final library size is typically 200--600bp with insert sizes ranging from 80--450bp. Final libraries are validated using bioanalyzer DNA chips and qPCR quantified using primers recognizing the Illumina adaptors. Libraries are pooled at equimolar ratios, quantified using qPCR (quantification of only the adaptor-ligated libraries) and loaded onto the NextSeq 500 flow cell at 1.8pM final concentration for pair end 75bp reads. 20--25 million mappable reads per sample were collected. Demultiplexed and quality filtered raw reads (fastq) generated from the NextSeq 500 were trimmed (adaptor sequences) using Flexbar 2.4 and aligned to the reference genome using TopHat version 2.0.9 ([@R55]). HT seq-count version 0.6.1 was used to generate gene counts and differential gene expression analysis was performed using Deseq2 ([@R1]). The normalized gene counts were used to plot the heatmaps using the heatplot package in R. To determine enriched functional groups in the RNA-seq data, KEGG pathway analysis was performed using DAVID ([@R19]; [@R20]).

### TR-FRET corepressor interaction assay {#S33}

The TR-FRET assay was performed in black low-volume 384-well plates (Greiner). Each well contained 4 nM 6xHistag-REV-ERBα LBD (human; residues 281--614) or 6xHistag-REV-ERBβ LBD (human; residues 212--579) protein expressed in and purified from *Escherichia coli* using nickel affinity and size exclusion chromatography; 1 nM LanthaScreen Elite Tb-anti-HIS Antibody; and 400 nM FITC-labeled peptide derived from the SMRT corepressor containing a N-terminal FITC label with a six-carbon linker (Ahx) and an amidated C terminus for stability in TR-FRET buffer (20 mm potassium phosphate, pH 7.4, 50 mm potassium chloride, 1 mm dithiothreitol, and 0.005% Tween-20). Ligand stocks were prepared via serial dilution in DMSO, added to wells in triplicate, and plates were incubated at 4°C for 2 h and read using BioTek Synergy Neo multimode plate reader. The Tb donor was excited at 340 nm; its fluorescence emission was monitored at 495 nm, and the acceptor FITC emission was measured at 520 nm; and the TR-FRET ratio was calculated as the signal at 520 nm divided by the signal at 495 nm. Data were plotted using GraphPad Prism as TR-FRET ratio versus ligand concentration and fit to sigmoidal dose response curve equation.

### Immunoblot Analysis {#S34}

T cells were washed once with phosphate-buffered saline and then incubated for 10 min at 4°C in 100 mL of TNT lysis buffer (50 mm Tris-Cl, pH 7.5, 150 mm NaCl, and 1% Triton X-100) containing protease inhibitors. Samples were then vortexed for 30 s and centrifuged (14,000RPM for 10 min). Protein levels in the supernatants were determined using a Coomassie protein assay kit, and 15 mg of protein from each sample was separated by SDSPAGE (10%) and transferred to a PVDF membrane and immunoblotted with primary antibodies: mouse RORγt and Actin. KLH-conjugated (LifeTein, LLC.) peptides were designed to generate paralog-specific antibodies recognizing epitopes spanning amino acid residues 268 to 279 of REV-ERBα and were injected in rabbits, similar to what has been previously described ([@R7]). Peptides were synthesized by LifeTein, LLC. (Somerset, NJ, USA). Immunization and serum collection were performed by Pocono Rabbit Farm and Laboratories (Canadensis, PA), and antibodies were purified by peptide affinity chromatography. Horseradish peroxidase-conjugated secondary antibodies were purchased from Jackson Immunoresearch. Detection of the bound antibody by enhanced chemiluminescence was performed according to the manufacturer's instructions.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S35}
---------------------------------------

All data are expressed as the mean ± SEM. All statistical analyses were performed using GraphPad PRISM 6. Student's t test was used for comparison between two groups. To compare differences between groups *in vivo*, a 2-way ANOVA with Bonferroni's multiple comparison test was performed if values were derived from a normal distribution. Where a normal distribution could not be confirmed or sample size was small, nonparametric Mann-Whitney U tests with a post hoc test were performed. A *p* value of \< 0.05 was considered statistically significant. The number of sample replicates and statistical cut-offs used in the analysis of genomics data are indicated in the figure legends or the text.

DATA AND SOFTWARE AVAILABILITY {#S36}
------------------------------

All next-generation sequencing data generated for this paper were deposited in the Gene Expression Omnibus (GEO) under accession number GEO: GSE122726.
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![The REV-ERBs Inhibit T~H~17 Cell Development\
(A) Quantitative real-time PCR analysis ofThelper cell lineage-specific transcription factorsT-bet (*Tbx21*), *Gata3, Foxp3*, RORα *(Rora)*, RORγt *(Rorc)*, REV-ERBα *(Nrldl)*, and REV-ERBβ *(Nr1d2)* under T~H~1, T~H~2, T~H~17, and inducible T regulatory cell (iTreg) conditions at 48 hr after T cell-activation compared to naive CD4+ T cells (n = 3).\
(B) Quantitative real-time PCR of *Il17a, Rora, Rorc, Nrldl*, and *Nr1d2* expression during T~H~17 cell differentiation. Data represent mean ± SEM (n = 3).\
(C) Immunoblot analysis of REV-ERBα and RORγt expression during T~H~17 cell differentiation (n = 4).\
(D) FACS analysis of IL-17A and IL-17F expression in T~H~17 cells transduced with empty vector (MIGR1), REV-ERBα, or REV-ERBβ. Cells were gated on live, GFP^+^ cells. Quantitative real-time PCR analysis of REV-ERBα and REV-ERBβ expression from sorted GFP^+^ T~H~17 cells transduced with MIGR1, REV-ERBα, or REV-ERBβ (n = 4).\
(E) FACS analysis of RORγt expression from T cell cultures shown in (D). Graph (right) indicates median fluorescent intensity (MFI) of RORγt expression in the FACS plots.\
(F) Quantitative real-time PCR of sorted GFP^+^ cells from (D) (n = 3).\
(G) Heatmap of differentially expressed genes in T~H~17 cells (false discovery rate \[FDR\], \<0.05).\
(H) KEGG pathway analysis of genes differentially expressed between MIGR1-, REV-ERBα--, and REV-ERBβ-overexpressing T~H~17 cells. p-actin was used as the internal control for quantitative real-time PCR. \*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001 determined using Student's t test. ns, not significant (p \> 0.05).](nihms-1517860-f0002){#F1}

![Loss of REV-ERBα Leads To Increased T~H~17-Mediated Autoimmunity\
(A) FACSanalysisfromT\|-\|17culturesderived from REV-ERBα^+/+^ (WT) and REV-ERBα^−/−^ (KO) mice. Graphs indicate percent IL-17A+IL-17F^+^ cells(top) and MFI of RORγt expression in the FACS plots (bottom) (n = 4).\
(B) Quantitative real-time PCR of T~H~17-mediated cytokines in T~H~17 cell cultures from WT and KO mice. β-actin was used as the internal control (n = 3).\
(C) Heatmap of differentially expressed genes between WT and KO T~H~17 cells. KEGG pathway analysis of genes differentially expressed between WT and KO T~H~17 cells. Venn diagram depicting the numbers of unique and shared genes differentially regulated in WT/KO and WT/RORγ^−/−^ T~H~17 cells (FDR, \<0.05).\
(D) Clinical EAE scores (left) and disease incidence (right) from WT and KO mice subjected to MOG-induced EAE.\
(E and F) Graphs summarizing the frequency of TCRβ^+^CD4^+^ cells (E) and Foxp3^+^ cells in the CNS of mice (F).\
(G) Graph representing FACS analysis of RORγt expression (left) and total IL-17Aexpression in RORγt+ cells (right) in theTCRp^+^CD4^+^ cells in the CNS of WT and KO mice.\
(H) FACS analysis and graph depicting the frequency of IL-17A^+^IFNγ^−^, IL-17A^+^IFNγ^+^, and IL-17A^−^IFNγ^+^ cells in the CNS ofWT and KO mice.\
Cellsweregated on live, CD45^+^TCRp^+^CD4^+^ cells. Each symbol representsan individual mouse (n = 4/group). Data represent mean ± SEM and are representative of two separate independent experiments generating similar results. Two-way ANOVA (clinical score) and Student'sttests were performed forstatistical analysis. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms-1517860-f0003){#F2}

![Loss of REV-ERBα in T Cells Exacerbates Colitis\
(A) Percent change in body weight, colon weights, colon lengths, and colon weight versus colon length ratios of *Rag1*^*−/−*^ recipient mice over 12 weeks post- adoptive transfer of WT, KO, or control (no cells, PBS) T cells.\
(B-D) FACS plots demonstrating frequencies of (B and D) RORγt^+^ and (C and D) CD25^+^Foxp3^+^ cells in the spleens and mesenteric lymph nodes (mLN) of recipient mice at the termination of the experiment.\
(E) FACS analysis and frequencies of IL-17A^+^IFNγ^−^, IL-17A^+^IFNγ^+^, and IL-17A^−^IFNγ^+^ cells in the spleens and mLNs of recipient mice. Cells were gated on live, CD45^+^CD3^+^CD4^+^ cells.\
(F) Quantitative real-time PCR analysis of cytokines and chemokines expressed in the proximal colon from *Rag1*^*−/−*^ mice receiving PBS, WT, or KO CD4^+^ T cells. 18s was used as the internal control.\
(G) Histology scores from colon and representative hematoxylin and eosin stained proximal colon sections from *Rag1*^*−/−*^ recipient mice12 weeks after transfer of naive CD4^+^ T cells. (×10 magnification, scale bars represent 200 mm; ×40 magnification, scale bars represent 50 mm) (n = 13 for WT, n = 15 for KO, and n = 3 for PBS).\
Data represent mean ± SEM. Two-way ANOVA (body weight) and Student's t tests were performed for statistical analysis. \*p \< 0.05, \*\*p \< 0.001, \*\*\*p \< 0.001, \*\*\*\*p\<0.0001.](nihms-1517860-f0004){#F3}

![REV-ERBα Competes with RORγt To Repress T~H~17 Cell Development\
(A) Schematic demonstrating REV-ERBα and RORγt competition for the *Il17a* locus.\
(B) Schematic of REV-ERBα constructs. Cotransfection assays in HEK293 cells demonstrating full-length (FL) and REV-ERBα DBD dose-dependently sup-presses *Il17a + CNS5* luciferase activity. EV refers to empty vector. (n = 5).\
(C) Cotransfection assay in HEK293 cellsdemonstratingthat FLand REV-ERBα DBD competeswith RORγt binding atthe*Il17a* + *CNS5* RORE. The concentration of RORγt was constant in all conditions labeled with a (+). (n = 5).\
(D) Cotransfection assay in EL4 cells demonstrating REV-ERBα competes with endogenous RORγt binding at the *Il17a + CNS5* RORE. P+I indicates 18-hr stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (n = 4).\
(E) FACS analysis of IL-17A and IFNγ expression in T~H~17 cells transduced with MIGR1, FLREV-ERBα, REV-ERBα DBD, or REV-ERBαΔDBD. Cells were gated on live, GFP^+^ cells (n = 4).\
(F) ChIP-qPCR of REV-ERBα binding at various sites in KO and WT T~H~17 cells collected on day 3. *(Il17a-p, Il17a* promoter).\
Data represent mean ± SEM (n = 4). \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 determined using Student's t test. ns, not significant (p \> 0.05).](nihms-1517860-f0005){#F4}

![REV-ERBα-Specific Small Molecules Suppress T~H~17 Cell Development and Function\
(A) Cotransfection assay in HEK293 cells using FL REV-ERBα, REV-ERBβ, and the *Il17a + CNS5* luciferase reporter. Graphs demonstrate that SR9009 and SR12418 dose-dependently drive REV-ERB-mediated repression of *Il17a + CNS5* luciferase activity. Data represent mean ± SEM (n = 4).\
(B) Mouse CD4^+^ T cells were differentiated under T~H~17 polarizing conditions and treated with vehicle (DMSO), SR9009, or SR12418. IL-17Aand IFNγ expression were analyzed by flow cytometry. Graphs indicate percent IL-17A^+^ cells and frequency of live cells in cultures with compound treatment (n = 3).\
(C) FACS analysis and graphs depicting MFI of RORγt expression in T~H~17 cultures treated with SR9009 and SR12418.\
(D) Quantitative real-time PCR of T~H~17-mediated cytokines in cells treated with vehicle (DMSO), SR9009 (5 mm), or SR12418(5 mm). Analysis was performed at 96 hr after T cell activation and compared to naive CD4^+^ T cells. β-actin was used as the internal control. Data represent mean ± SEM (n = 3).\
(E) FACS analysis of IL-17A and IFNγ expression inT~H~7 cellstransduced with MIGR1 RORγt and treated with vehicle (DMSO), SR9009, or SR12418 for 48 hr at the indicated doses. Cells were gated on live, GFP^+^ cells (n = 4).\
(F) FACS analysis of thymocytes from mice treated with vehicle, SR2211, SR9009, or SR12418 for 72 hr.\
Graphs depict quantification of total thymocyte number, double positive percentage, and double positive number in each group (n = 5/group). Data represent mean ± SEM. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001 determined using Student's t test. ns, not significant (p \> 0.05).](nihms-1517860-f0006){#F5}

![SR12418 Potently Suppresses the Development and Severity of EAE\
(A) Clinical EAE scores (left) from mice subjected to MOG-induced EAE and treated with vehicle (10/10/80 formulation of DMSO/Tween80/H~2~O) or SR12418 (i.p., 50mg/kg, b.i.d.) for the duration of the experiment. Middle and right graphs demonstrate the percent incidence of disease and percent change in body weight overtime between groups, respectively (n = 8--10/group).\
(B) Frequencies and cell counts of CD3~+~CD4^+^ cells in the draining LNs and CNS of mice at peak of disease. V, vehicle; SR, SR12418-treated mice (n = 8, V; n = 7, SR).\
(C) Graphs depicting the frequencies and cell counts of CD4^+^GM^−^CSF^+^ cells in LN and CNS of mice at peak of disease.\
(D) FACS analysis, frequencies, and cell counts of RORγt^+^ cells in LNs and CNS of mice at peak of disease.\
(E) FACS analysis, frequencies, and cell counts of IL-17A^+^IFNγ^−^, IL-17A^+^IFNγ^+^, and IL-17A^−^IFNγ^+^ cells in the LN and CNS of mice at peak of disease.\
Cells were gated on live, CD45^+^CD3^+^CD4^+^ cells. Data are mean ± SEM and representative of three separate, independent experiments with similar results. Two-way ANOVA (clinical score) and Student's t tests were performed for statistical analysis. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.](nihms-1517860-f0007){#F6}

![SR12418 Is Effective When Used in Intervention Studies of Colitis and Relapsing-Remitting EAE\
(A) Schematic of the adoptive T cell transfer colitis model treatment design.\
(B-E) FACS plots and graphs demonstrating frequencies of (B) α4β7^+^, (C) RORγt^+^, (D) IL-17A^+^IFNγ^−^, IL-17A^+^IFNγ^+^, and IL-17A^−^IFNγ^+^, and (E) CD25^+^Foxp3^+^ T cells in the colons of recipient mice. Cells were gated on live, CD45^+^CD3^+^CD4^+^ cells. V, vehicle; SR, SR12418. Data are mean ± SEM (n = 10/group; PBS, n = 2).\
(F) Clinical EAE scores from mice subjected to PLP-induced EAE and treated with vehicle or SR12418 (i.p., 50 mg/kg, b.i.d.) starting on day 18 and continued for the duration of the experiment (n = 17/group).\
(G-K) Graphs demonstrating decreased frequencies and cell numbers of (G) effector CD4 and CD8 T cells and (H) CCR6^+^ T cells in the CNS of mice treated with SR12418. FACS plots and graphs demonstrating frequencies and/or cell numbers of (I) RORγt^+^, (J) RORγt^+^ GM-CSF^+^, and (K) IL-17A^+^IFNγ^−^, IL-17A^+^IFNγ^+^, and IL-17A^−^IFNγ^+^ T cells in the CNS of SR12418-treated mice relative to vehicle controls.\
Cells were gated on live, CD45^+^CD3^+^CD4^+^CD44^+^cells (n = 7, vehicle; n = 6, SR12418). Data represent mean ± SEM. Two-way ANOVA (clinical score) and Student's t tests were performed for statistical analysis. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms-1517860-f0008){#F7}

###### KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                      SOURCE                      IDENTIFIER
  ---------------------------------------------------------------------------------------- --------------------------- ----------------------------------------
  Antibodies                                                                                                           
  LanthaScreen Elite Tb-anti-His Antibody                                                  Thermo Fisher               Cat \# PV5863
  Mouse RORγt (immunoblot)                                                                 eBioscience                 Cat \# MA5-16227; RRID: AB_2537745
  Actin, clone C4                                                                          EMD Millipore               Cat \# MAB1501
  Rabbit polyclonal anti-REV-ERBα                                                          This paper                  N/A
  Purified anti IL-4, clone 11B11                                                          Biolegend                   Cat\# 504115; RRID: AB_2295885
  Purified anti-IFNγ, clone XMG1.2                                                         Biolegend                   Cat\# 505834; RRID: AB_11150776
  Soluble anti-CD3, clone 2C11                                                             eBioscience                 Cat\# 16-0031-86; RRID: AB_468849
  Soluble anti-CD28, clone 37.51                                                           eBioscience                 Cat\# 16-0281-86; RRID: AB_468923
  Goat anti-Hamster IgG                                                                    MP Biomedicals              Cat \# 856984
  BUV395 Hamster anti-mouse CD3e, clone 145-2C11                                           BD Biosciences              Cat\# 563565; RRID: AB_2738278
  BV711 anti-mouse CD4, clone RM4-5                                                        Biolegend                   Cat\# 100549; RRID:AB_11219396
  FITC anti-mouse CD8a, clone 53-6.7                                                       eBioscience                 Cat\# 11-0081-85; RRID: AB_464916
  FITC anti-mouse CD19, clone eBio1D3                                                      eBioscience                 Cat\# 11-0193-86; RRID: AB_657665
  BV605 anti-mouse CD25, clone PC61                                                        Biolegend                   Cat\# 102035; RRID: AB_11126977
  PerCP-Cy5.5 anti-mouse/human CD44, clone IM7                                             Biolegend                   Cat\# 103031; RRID: AB_2076206
  A700 anti-mouse CD45, clone 30-F11                                                       Biolegend                   Cat\# 103128; RRID: AB_493715
  BV421 Rat anti-mouse CD62L, clone MEL-14                                                 BD Biosciences              Cat\# 562910; RRID: AB_2737885
  eFluor 660 anti-mouse CCR6, clone sirx6                                                  eBioscience                 Cat\# 50-7196-80; RRID: AB_11218711
  Pe/Cy7 anti-mouse CXCR3, clone CXCR3-173                                                 Biolegend                   Cat\# 126515; RRID: AB_2086740
  FITC anti-mouse B220, clone RA3-6B2                                                      eBioscience                 Cat\# 11-0452-82; RRID: AB_465054
  eFluor 660 anti-mouse Foxp3, clone FJK-16 s                                              eBioscience                 Cat\# 50-5773-82; RRID: AB_11218868
  PE anti-mouse GM-CSF, clone MP1-22E9                                                     Biolegend                   Cat\# 505405; RRID: AB_315381
  PE anti-mouse IL-4, clone 11B11                                                          Biolegend                   Cat\# 504103; RRID: AB_315317
  PE/Cy7 anti-mouse IL-10                                                                  Biolegend                   Cat\# 505025; RRID: AB_11149682
  BV421 anti-mouse IL-17A, clone TC11-18H10                                                BD Biosciences              Cat\# 563354; RRID: AB_2687547
  PE anti-mouse IL-17F, clone eBio18F10                                                    eBioscience                 Cat\# 12-7471-82; RRID: AB_1210742
  PE/Cy7 anti-mouse IFNγ, clone AMG1.2                                                     eBioscience                 Cat\# 25-7311-82; RRID: AB_469680
  PE-CF594 anti-mouse RORγt, clone Q31-378                                                 BD Biosciences              Cat\# 562684; RRID: AB_2651150
  BV510 anti-mouse TCRβ, clone H57-597                                                     BD Biosciences              Cat\# 563221; RRID: AB_2738078
  PE/Cy7 anti-mouse TNFα, clone MP6-XT22                                                   eBioscience                 Cat\# 25-7321-82; RRID: AB_11042728
  Mouse Fc Block (purified anti-CD16/32), clone 24G2                                       BD Biosciences              Cat\# 553141; RRID: AB_394656
  Bacterial and Virus Strains                                                                                          
  BL21(DE3) E.coli cells                                                                   New England Biolabs         Cat \# C2527
  Chemicals, Peptides, and Recombinant Proteins                                                                        
  FITC-SMRT ID2 (FITC-NH-TNMGLEAIIRKALMGKYDQWEE)                                           LifeTein, LLC.              N/A
  MOG 35-55 peptide                                                                        LifeTein, LLC.              LT12018, LT051716
  Incomplete Freunds Adjuvant (IFA)                                                        Fisher                      Cat\#PI-77145
  Pertussis Toxin                                                                          List Biological Labs        Cat\# 180
  H27Ra TB                                                                                 Difco                       Cat\# DF3114338
  SR2211                                                                                   [@R27]                      Dr. Ted Kamenecka
  SR9009                                                                                   [@R50]                      Dr. Ted Kamenecka
  Tween 80                                                                                 Sigma-Aldrich               P8074
  Kolliphor EL (Crempahor)                                                                 Sigma-Aldrich               C5135
  Phorbol 12-myristate 13-acetate (PMA)                                                    Tocris                      Cat \# 1201
  Lonomycin                                                                                Sigma-Aldrich               Cat \# I0634
  Lympholyte-M                                                                             Accurate Chemicals          Cat\# ACL5035
  Percoll                                                                                  Sigma-Aldrich               Cat \#P1644
  TRIzol                                                                                   Life Technologies           Cat\# 10296-028
  FuGene                                                                                   Promega                     Cat \#E2311
  Lipofectamine 3000                                                                       Invitrogen                  Cat \#L-3000008
  Recombinant mouse IL-12                                                                  R & D Systems               Cat\# 419-ML
  Recombinant mouse IL-4                                                                   R & D Systems               Cat \# 404-ML
  Recombinant human TGFβ                                                                   R & D Systems               Cat\# 240-B
  Recombinant mouse IL-6                                                                   R & D Systems               Cat\# 406-ML
  Recombinant mouse IL-23                                                                  R & D Systems               Cat\# 1887-ML
  Recombinant mouse IFNγ                                                                   R & D Systems               Cat\# 485-MI-100
  Recombinant mouse IL-1β                                                                  R & D Systems               Cat\# 410-ML
  Recombinant mouse IL-21                                                                  R & D Systems               Cat\# 594-ML
  Xhol                                                                                     NEB                         Cat\# R0146L
  Hpal                                                                                     NEB                         Cat\# R0105L
  BamHI-HF                                                                                 NEB                         Cat\# R3136L
  Hindlll-HF                                                                               NEB                         Cat\# R3104L
  GolgiStop                                                                                BD Biosciences              Cat\# 554724
  RNase-free DNasel                                                                        Sigma-Aldrich               Cat\# 4716728001
  Liberase TL                                                                              Sigma-Aldrich               Cat\# 5401020001
  EDTA                                                                                     Amresco                     Cat\# E177
  DTT (Dithiothreitol)                                                                     Sigma-Aldrich               Cat\# DTTRO
  DMEM                                                                                     Mediatech                   Cat\# 10-017-CV
  IMDM                                                                                     Life Technologies           Cat\# 30980-097
  L-glutamine                                                                              Life Technologies           Cat\# 25030-081
  Penicillin/streptomycin                                                                  Life Technologies           Cat\# 15140-122
  FBS                                                                                      Gemini                      Cat\# 100-106
  2-Mercaptoethanol                                                                        Sigma-Aldrich               Cat\# M3148
  Fixable viability dye eFluor 780                                                         eBioscience                 Cat\# 65-0865-14
  Fixable viability dye eFluor 506                                                         eBioscience                 Cat\# 65-0866-14
  6xHistag REV-ERBα LBD                                                                    Homemade                    Dr. Doug Kojetin
  6xHistag REV-ERBβ LBD                                                                    [@R37].                     Dr. Doug Kojetin
  Polybrene                                                                                SantaCruz Biotechnology     Cat \# sc-134220
  Critical Commercial Assays                                                                                           
  EasySep mouse Naive CD4+ T cell isolation kit                                            StemCell Tech               Cat\# 19765
  RNeasy Plus Micro Kit                                                                    QIAGEN                      Cat \#74034
  RNeasy Mini kit                                                                          QIAGEN                      Cat \# 74106
  qScript cDNA synthesis Kit                                                               QuantaBio/VWR               Cat \#101414-100
  PerfeCTa SYBR Green FastMix                                                              QuantaBio/VWR               Cat\# 101414-280
  Dual-Glo Luciferase Assay System                                                         Promega                     Cat \# E2940
  Britelite Plus                                                                           Perkin Elmer                Cat \#6066769
  Amaxa EL4 Nucleofector kit                                                               Lonza                       Cat \#VCA-1005
  Zippy Plasmid Maxi Prep Kits                                                             Zymo                        Cat \# D4028
  QIAquick Gel extraction kit                                                              QIAGEN                      Cat\# 28704
  Pierce Coomassie (Bradford) Protein Assay kit                                            Thermo Fisher               Cat\# 23200
  TruSeq Stranded Total RNA Ribo-Zero Gold (H/M/R)                                         Illumina                    Cat\# RS-122-2301
  TruSeq Stranded Total RNA v2 with rRNA depletion                                         Illumina                    Cat\# RS-122-2001
  SuperSignal West Femto Chemiluminescence                                                 Thermo Fisher               Cat\# PI34095
  eBioscience Foxp3 Transcription Factor staining kit                                      Thermo Fisher               Cat \# 00-5523-00
  MOG 35-55/CFA Emulsion PTX (EAE induction kit)                                           Hooke Laboratories          EK-2110
  PLP 139-151/CFA Emulsion PTX (EAE induction kit)                                         Hooke Laboratories          EK-2120
  SimpleChIP Plus Sonication Chromatin IP kit                                              Cell Signaling Technology   Cat \# 56383
  Deposited Data                                                                                                       
  REV-ERB overexpression RNA-seq                                                           This paper                  GEO: GSE122726
  REV-ERBα WT versus KO RNA-seq                                                            This paper                  GEO: GSE122726
  Experimental Models: Cell Lines                                                                                      
  HEK293 cells                                                                             ATCC                        Cat\# CRL-1573; RRID: CVCL_0045
  PlatE cells                                                                              Cell Biolabs, Inc           Cat \# RV-101
  EL4 cells                                                                                ATCC                        ATCC\# TIB-39; RRID: CVCL_0255
  Experimental Models: Organisms/Strains                                                                               
  C57BL/6                                                                                  Jackson Laboratories        Stock\# 000664
  SJL/J                                                                                    Jackson Laboratories        Stock \# 000686
  KO (B6.Cg-*Nr1d1*^*tm1Ven*^/LazJ)                                                        Jackson Laboratories        Stock \# 018447; RRID: IMSR_JAX:018447
  *Rag1*^*−/−*^ (B6.129S7-Rag7^*tm1Mom*^/J)                                                Jackson Laboratories        Stock \# 003145
  Rorc^*fi/fi*^(B6(Cg)-fiorc^*tm3Litt/J*^)                                                 Jackson Laboratories        Stock \# 008771
  CD4 Cre (Tg(Cd4-cre)1Cwi/BfluJ)                                                          Jackson Laboratories        Stock \# 017336
  Oligonucleotides                                                                                                     
  Primers for qRT-PCR, see [Table S3](#SD1){ref-type="supplementary-material"}             This paper                  N/A
  ChIP primers *Il17a promoter*, see [Table S3](#SD1){ref-type="supplementary-material"}   [@R63]                      N/A
  ChIP primers *Il17a CNS2*, see [Table S3](#SD1){ref-type="supplementary-material"}       [@R63]                      N/A
  ChIP primers *Cry1*, see [Table S3](#SD1){ref-type="supplementary-material"}             This paper                  N/A
  ChIP primers *Nfil3*, see [Table S3](#SD1){ref-type="supplementary-material"}            [@R62]                      N/A
  ChIP primers *Rorc*, see [Table S3](#SD1){ref-type="supplementary-material"}             This paper                  N/A
  ChIP primers *Hprt*, see [Table S3](#SD1){ref-type="supplementary-material"}             This paper                  N/A
  Recombinant DNA                                                                                                      
  MIGR1                                                                                    Addgene                     Addgene plasmid \# 9044
  MIGR1 REVERBα                                                                            Homemade                    N/A
  MIGR1 REVERBβ                                                                            Homemade                    N/A
  MIGR1 REVERBα DBD                                                                        Homemade                    N/A
  MIGR1 REVERBα ΔDBD                                                                       Homemade                    N/A
  MIGR1 NFIL3                                                                              Homemade                    N/A
  pLMPd-Ametrine                                                                           [@R5]                       Dr. Matthew Pipkin
  ShRNAmir: *Cd8a*                                                                         TransOMIC                   Cat\# TLMSU1400-12525
  ShRNAmir: *Nr1d2*                                                                        TransOMIC                   Cat\# TRMSU2000-353187
  shRNAmir:*Nfil3*                                                                         TransOMIC                   Cat\# TRMSU2000-18030
  MIGR1 RORγt                                                                              Addgene                     Addgene plasmid \#24069
  pGL4 *mll17a-2kb promoter+CNS5* luciferase                                               [@R63]                      Addgene plasmid \# 20128
  pGL3 *Bmal1* luciferase                                                                  [@R61]                      Dr. Tom Burris
  pGL4.73 Renilla                                                                          Promega                     Cat\# E691A
  pcDNA3.1 REV-ERBα                                                                        Homemade                    N/A
  pcDNA3.1 REV-ERBα DBD                                                                    Homemade                    N/A
  pcDNA3.1 REVERBα ΔDBD                                                                    Homemade                    N/A
  pcDNA3.1 RORγt                                                                           Homemade                    N/A
  pCL-Eco packaging vector                                                                 [@R42]                      Addgene plasmid \#12371
  Software and Algorithms                                                                                              
  GraphPad Prism                                                                           GraphPad Software           <https://www.graphpad.com>
  FlowJo (Version 10.4.1)                                                                  TreeStar                    <https://www.flowjo.com>
  R studio                                                                                 R studio                    N/A
  DAVID                                                                                    LHRI                        <https://david.noifcrf.gov>

###### Highlights

-   REV-ERBα is upregulated in T~H~17 cells

-   REV-ERBα deficiency exacerbates T~H~17-mediated diseases, including EAE and colitis

-   REV-ERBα competes with RORγt to modulate T~H~17-signature genes, including *Il17a*

-   REV-ERBα-specific ligands suppress the development and progression of autoimmunity
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